Authors
- . Ebrahim Salehifar 1
- . Afshin Shiva 2
- . Mona Moshayedi 3
- . Taravat Samiei Kashi 4
- . Aroona Chabra 4
1 Department of Clinical Pharmacy, Thalassemia Research Center, Mazandaran University of Medical Sciences, Sari, Iran
2 Department of Clinical Pharmacy, Urmia University of Medical Sciences, Urmia, Iran Department of Clinical Pharmacy, Pharmaceutical Sciences Research Center, Mazandaran University of Medical Sciences, Sari, Iran
3 Department of Clinical Pharmacy, Pharmaceutical Sciences Research Center, Mazandaran University of Medical Sciences, Sari, Iran
4 Student's Research Committee, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran
Abstract
Objective: The inappropriate use of antibiotics remains the primary factor in antimicrobial
drug resistance. In this study, we evaluate the use of meropenem in surgical/medical wards
of Imam Khomeini Tertiary Referral Hospital, Sari, Iran.
Methods: This retrospective observational study was used to assess rational use of
meropenem. The study was conducted by reviewing medical records of 100 admitted patients
who received meropenem during March 2013 to January 2014.
Findings: Meropenem was prescribed most frequently in Intensive Care Unit (22%), and
pneumonia was the most common diagnosis(35%). The third‑generation cephalosporins were
the most frequently prescribed antimicrobials after meropenem (53%). In 21% of the patients,
imipenem was changed to meropenem. Most of the inappropriate uses were seen in terms
of frequency of meropenem use (34%), followed by duration of meropenem therapy (28%).
Conclusion: Comparing our study results has shown higher inappropriate use. It is necessary
to take action to improve prescribing habit in order to reduce the unnecessary usage of
antibiotic thus enhance rational antibiotic use.
Keywords
use in intensive care units of a tertiary care hospital in Turkey.
J Hosp Infect 2005;59:53‑61.
2. McIntosh W, Dean W. Factors associated with the
inappropriate use of antimicrobials. Zoonoses Public Health
2015;62 Suppl 1:22‑8.
3. May L, Cosgrove S, L’Archeveque M, Talan DA, Payne P,
Jordan J, et al. A call to action for antimicrobial stewardship in
the emergency department: Approaches and strategies. Ann
Emerg Med 2013;62:69‑77.e2.
4. Pournaras S, Vrioni G, Neou E, Dendrinos J, Dimitroulia E,
PoulouA, et al. Activity of tigecycline alone and in combination
with colistin and meropenem against Klebsiella pneumoniae
carbapenemase (KPC)‑producing Enterobacteriaceae strains by
time‑kill assay. Int J Antimicrob Agents 2011;37:244‑7.
5. Suh B, Bae IK, Kim J, Jeong SH, Yong D, Lee K. Outbreak
of meropenem‑resistant Serratia marcescens comediated by
chromosomal AmpC beta‑lactamase overproduction and
outer membrane protein loss. Antimicrob Agents Chemother
2010;54:5057‑61.
6. Ejikeugwu PC, Ugwu CM, Araka CO, Gugu TH, Iroha IR,
Adikwu MU. Imipenem and meropenem resistance amongst
ESBL producing Escherichia coli and Klebsiella pneumoniae
clinical isolates. Int Res J Microbiol 2012;3:339‑44.
7. Shigemoto N, Kuwahara R, Kayama S, Shimizu W, Onodera M,
Yokozaki M, et al. Emergence in Japan of an imipenem‑susceptible,
meropenem‑resistant Klebsiella pneumoniae carrying blaIMP‑6.
Diagn Microbiol Infect Dis 2012;72:109‑12.
8. McEvoy GK, editor. AHFS Drug Information. Bethesda (MD):
American Society of Health‑System Pharmacists, Inc.; 2015.
9. Gilbert DN, Moellering RC, Eliopoulos GM, Chambers HF,
Saag MS. The Sanford Guide to Antimicrobial Therapy 2014.
Sperryville: Antimicrobial Therapy; 2014.
10. ShivaA, Salehifar E, Amini M, Ala S, Rafati MR, Ganji R. Drug
utilization evaluation of imipenem in an educational hospital
in Mazandaran Province. Pharm Sci 2014;20:12‑7.
11. Hawkey PM, Livermore DM. Carbapenem antibiotics for
serious infections. BMJ 2012;344:e3236.
12. Hornik CP, Herring AH, Benjamin DK Jr, Capparelli EV,
Kearns GL, van den Anker J, et al. Adverse events associated
with meropenem versus imipenem/cilastatin therapy in a large
retrospective cohort of hospitalized infants. Pediatr Infect Dis
J 2013;32:748‑53.
13. Saito T, Sawazaki R, Ujiie K, Oda M, Saitoh H. Possible factors
involved in oral inactivity of meropenem, a carbapenem
antibiotic. Pharmacol Pharm 2012;3:201‑6.
14. Tarcea Bizo P, Dumitras D, Popa A. Evaluation of restricted
antibiotic use in a hospital in Romania. Int J Clin Pharm
2015;37:452‑6.
15. Khan MU, Yousuf RI, Shoaib MH. Drug utilization evaluation
of meropenem and correlation of side effects with renal status
of patients in a teaching based hospital. Pak J Pharm Sci
2014;27:1503‑8.
16. Mahini S, Hayatshahi A, Torkamandi H, Gholami KH,
Javadi MR. Carbapenem utilization in critically Ill patients.
J Pharm Care 2014;1:141‑4.
17. Raveh D, Muallem‑Zilcha E, Greenberg A, Wiener‑Well Y,
Schlesinger Y, Yinnon AM. Prospective drug utilization
evaluation of three broad‑spectrum antimicrobials:
Cefepime, piperacillin‑tazobactam and meropenem. QJM
2006;99:397‑406.
)